Standard

Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. / Забегалов, Константин; Колесникова, Татьяна; Хацко, Сергей; Волгин, Андрей; Яковлев, Олег; Амстиславская, Тамара; Алексеева, Полина; Мешалкина, Дарья Андреевна; Friend, Ashton; Bao, Wandong; Демин, Константин Андреевич; Гайнетдинов, Рауль Радикович; Калуев, Алан Валерьевич.

в: European Journal of Pharmacology, Том 829, 15.06.2018, стр. 129-140.

Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование

Harvard

Забегалов, К, Колесникова, Т, Хацко, С, Волгин, А, Яковлев, О, Амстиславская, Т, Алексеева, П, Мешалкина, ДА, Friend, A, Bao, W, Демин, КА, Гайнетдинов, РР & Калуев, АВ 2018, 'Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models', European Journal of Pharmacology, Том. 829, стр. 129-140. https://doi.org/10.1016/j.ejphar.2018.04.003

APA

Забегалов, К., Колесникова, Т., Хацко, С., Волгин, А., Яковлев, О., Амстиславская, Т., Алексеева, П., Мешалкина, Д. А., Friend, A., Bao, W., Демин, К. А., Гайнетдинов, Р. Р., & Калуев, А. В. (2018). Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. European Journal of Pharmacology, 829, 129-140. https://doi.org/10.1016/j.ejphar.2018.04.003

Vancouver

Забегалов К, Колесникова Т, Хацко С, Волгин А, Яковлев О, Амстиславская Т и пр. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. European Journal of Pharmacology. 2018 Июнь 15;829:129-140. https://doi.org/10.1016/j.ejphar.2018.04.003

Author

Забегалов, Константин ; Колесникова, Татьяна ; Хацко, Сергей ; Волгин, Андрей ; Яковлев, Олег ; Амстиславская, Тамара ; Алексеева, Полина ; Мешалкина, Дарья Андреевна ; Friend, Ashton ; Bao, Wandong ; Демин, Константин Андреевич ; Гайнетдинов, Рауль Радикович ; Калуев, Алан Валерьевич. / Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. в: European Journal of Pharmacology. 2018 ; Том 829. стр. 129-140.

BibTeX

@article{ac353c39341243c2a7b47f32b1baf132,
title = "Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models",
abstract = "Antidepressant drugs are currently one of the most prescribed medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS is a common problem in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. Clinically, ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and emphasize how using animal models may help generate important translational insights into human ADS condition, its prevention and therapy.",
keywords = "Animal models, Antidepressants, Depression, Discontinuation syndrome, Side effects",
author = "Константин Забегалов and Татьяна Колесникова and Сергей Хацко and Андрей Волгин and Олег Яковлев and Тамара Амстиславская and Полина Алексеева and Мешалкина, {Дарья Андреевна} and Ashton Friend and Wandong Bao and Демин, {Константин Андреевич} and Гайнетдинов, {Рауль Радикович} and Калуев, {Алан Валерьевич}",
note = "Funding Information: The research was supported by the Russian Foundation for Basic Research (RFBR) grant 16-04-00851 to АVK. RRG was supported by a Russian Science Foundation (RSF) grant 14-50-00069. KAD and DAM are supported by the RFBR grants 18-34- 00996 and 18-315-00375, respectively. Appendix A",
year = "2018",
month = jun,
day = "15",
doi = "10.1016/j.ejphar.2018.04.003",
language = "English",
volume = "829",
pages = "129--140",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models

AU - Забегалов, Константин

AU - Колесникова, Татьяна

AU - Хацко, Сергей

AU - Волгин, Андрей

AU - Яковлев, Олег

AU - Амстиславская, Тамара

AU - Алексеева, Полина

AU - Мешалкина, Дарья Андреевна

AU - Friend, Ashton

AU - Bao, Wandong

AU - Демин, Константин Андреевич

AU - Гайнетдинов, Рауль Радикович

AU - Калуев, Алан Валерьевич

N1 - Funding Information: The research was supported by the Russian Foundation for Basic Research (RFBR) grant 16-04-00851 to АVK. RRG was supported by a Russian Science Foundation (RSF) grant 14-50-00069. KAD and DAM are supported by the RFBR grants 18-34- 00996 and 18-315-00375, respectively. Appendix A

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Antidepressant drugs are currently one of the most prescribed medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS is a common problem in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. Clinically, ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and emphasize how using animal models may help generate important translational insights into human ADS condition, its prevention and therapy.

AB - Antidepressant drugs are currently one of the most prescribed medications. In addition to treatment resistance and side effects of antidepressants, their clinical use is further complicated by antidepressant discontinuation syndrome (ADS). ADS is a common problem in patients following the interruption, dose reduction, or discontinuation of antidepressant drugs. Clinically, ADS resembles a classical drug withdrawal syndrome, albeit differing from it because antidepressants generally do not induce addiction. The growing clinical importance and prevalence of ADS necessitate novel experimental (animal) models of this disorder. Currently available preclinical models of ADS are mainly rodent-based, and study mostly serotonergic antidepressants and their combinations. Here, we systematically assess clinical ADS symptoms and discuss current trends and challenges in the field of experimental (animal) models of ADS. We also outline basic mechanisms underlying ADS pathobiology, evaluate its genetic, pharmacological and environmental determinants, and emphasize how using animal models may help generate important translational insights into human ADS condition, its prevention and therapy.

KW - Animal models

KW - Antidepressants

KW - Depression

KW - Discontinuation syndrome

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=85046350588&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2018.04.003

DO - 10.1016/j.ejphar.2018.04.003

M3 - Review article

VL - 829

SP - 129

EP - 140

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -

ID: 33277881